Global Information
회사소개 | 문의 | 비교리스트

주사 : 파이프라인 리뷰

Rosacea - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 192813
페이지 정보 영문 90 Pages
가격
US $ 2,000 ₩ 2,396,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,792,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,189,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


주사 : 파이프라인 리뷰 Rosacea - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 90 Pages

주사란 피부와 때로는 눈에 영향을 미치는 장기적 질병으로, 발적(적색)·부스럼을 유발합니다. 증상에는 안면의 빈번한 발적 또는 안면 홍조, 피하의 작은 붉은 선, 코의 팽창 및 일반적으로 이마·턱·볼의 피부가 두꺼운 증상 등이 있습니다. 소인에는 연령 및 주사 가족력이 포함됩니다. 치료에는 항생제 및 여드름약이 이용됩니다.

주사 치료제의 개발 상황에 대해 조사분석했으며, 파이프라인 제품의 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등에 관한 정보를 정리하여 전해드립니다.

목차

서론

주사 개요

치료제 개발

  • 파이프라인 제품 : 개요
  • 파이프라인 제품 : 기업별
  • 개발중인 제품 : 기업별

치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

치료제 개발에 참여하고 있는 기업

  • Almirall SA
  • Amorepacific Corp
  • BioPharmX Inc
  • Cutanea Life Sciences Inc
  • ELORAC Inc
  • Foamix Pharmaceuticals Ltd
  • Hovione FarmaCiencia SA
  • Promius Pharma LLC
  • Sol-Gel Technologies Ltd

약제 개요(제품 설명·작용기서·R&D 진척 상황)

휴지 상태 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

  • 최신 뉴스와 프레스 릴리스

부록

도표

KSA 17.11.02

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Rosacea, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Rosacea - Pipeline by Accuitis Pharmaceuticals Inc, H1 2020
  • Rosacea - Pipeline by Afecta Pharmaceuticals Inc, H1 2020
  • Rosacea - Pipeline by Aiviva BioPharma Inc, H1 2020
  • Rosacea - Pipeline by AlfaSigma SpA, H1 2020
  • Rosacea - Pipeline by AOBiome LLC, H1 2020
  • Rosacea - Pipeline by Biomimetix JV LLC, H1 2020
  • Rosacea - Pipeline by BioPharmX Inc, H1 2020
  • Rosacea - Pipeline by Botanix Pharmaceuticals Ltd, H1 2020
  • Rosacea - Pipeline by Cellix Bio Pvt Ltd, H1 2020
  • Rosacea - Pipeline by Cutanea Life Sciences Inc, H1 2020
  • Rosacea - Pipeline by Dermata Therapeutics LLC, H1 2020
  • Rosacea - Pipeline by ELORAC Inc, H1 2020
  • Rosacea - Pipeline by Emeriti Pharma AB, H1 2020
  • Rosacea - Pipeline by GlycoMira Therapeutics Inc, H1 2020
  • Rosacea - Pipeline by Hovione FarmaCiencia SA, H1 2020
  • Rosacea - Pipeline by Maruho Co Ltd, H1 2020
  • Rosacea - Pipeline by Matrisys Bioscience Inc, H1 2020
  • Rosacea - Pipeline by Menlo Therapeutics Inc, H1 2020
  • Rosacea - Pipeline by Sol-Gel Technologies Ltd, H1 2020
  • Rosacea - Pipeline by Sunny Pharmtech Inc, H1 2020
  • Rosacea - Pipeline by Tarsus Pharmaceuticals Inc, H1 2020
  • Rosacea - Pipeline by TWi Biotechnology Inc, H1 2020
  • Rosacea - Dormant Projects, H1 2020
  • Rosacea - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Rosacea - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Rosacea, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rosacea - Pipeline Review, H1 2020, provides an overview of the Rosacea (Dermatology) pipeline landscape.

Rosacea is a chronic and potentially life-disruptive disorder primarily of the facial skin, often characterized by flare-ups and remissions. Symptoms include frequent redness of the face, or flushing, small, red lines under the skin, a swollen nose and thick skin, usually on the forehead, chin, and cheeks. The predisposing factors include age and family history of rosacea. Treatment includes antibiotics and acne drugs.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rosacea - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Rosacea (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rosacea (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Rosacea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 10, 5 and 7 respectively.

Rosacea (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rosacea (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Rosacea (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rosacea (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rosacea (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rosacea (Dermatology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rosacea (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rosacea (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Rosacea - Overview
    • Rosacea - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Rosacea - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Rosacea - Companies Involved in Therapeutics Development
    • Accuitis Pharmaceuticals Inc
    • Afecta Pharmaceuticals Inc
    • Aiviva BioPharma Inc
    • AlfaSigma SpA
    • AOBiome LLC
    • Biomimetix JV LLC
    • BioPharmX Inc
    • Botanix Pharmaceuticals Ltd
    • Cellix Bio Pvt Ltd
    • Cutanea Life Sciences Inc
    • Dermata Therapeutics LLC
    • ELORAC Inc
    • Emeriti Pharma AB
    • GlycoMira Therapeutics Inc
    • Hovione FarmaCiencia SA
    • Maruho Co Ltd
    • Matrisys Bioscience Inc
    • Menlo Therapeutics Inc
    • Sol-Gel Technologies Ltd
    • Sunny Pharmtech Inc
    • Tarsus Pharmaceuticals Inc
    • Twi Biotechnology Inc
  • Rosacea - Drug Profiles
    • AC-701 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACUD-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AFX-4031 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AIV-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • B-244 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • benzoyl peroxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMX-010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BPX-04 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BTX-1702 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • carbamide peroxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLX-1621 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLXDER-621 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLXDER-622 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLXDER-623 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DMT-210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • doxycycline hyclate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EP-0003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FMX-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GM-0111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HY-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-1220 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MSB-03 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omiganan pentahydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • phenylbutyrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rifaximin DR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TP-04 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Rosacea - Dormant Projects
  • Rosacea - Discontinued Products
  • Rosacea - Product Development Milestones
    • Featured News & Press Releases
      • Feb 18, 2020: Foamix announces integrated efficacy results from the FMX103 1.5% Topical Minocycline Foam Phase 3 program for Rosacea
      • Feb 13, 2020: Sol-Gel announces positive topline results from open-label, long-term safety study of Epsolay for treatment up to 52 Weeks
      • Feb 06, 2020: Foamix announces publication of Phase 3 Studies evaluating FMX103 for the treatment of papulopustular rosacea in Journal of the American Academy of Dermatology
      • Jan 21, 2020: Sol-Gel announces presentation Epsolay at the 16th Annual Maui Derm for Dermatologists 2020 Meeting
      • Dec 09, 2019: Botanix initiates BTX 1702 rosacea study
      • Oct 23, 2019: Foamix enters into manufacturing and supply agreement For FMX103
      • Oct 17, 2019: Foamix announces FDA acceptance of its New Drug Application for FMX103 Minocycline foam for the treatment of Moderate-to-Severe Papulopustular Rosacea
      • Oct 16, 2019: Sol-Gel to present on potential of Sol-Gel Microencapsulation Technology in Rosacea at 39th Annual Fall Clinical Dermatology Conference
      • Oct 10, 2019: Foamix to present data on FMX-103 at 39th Annual Fall Clinical Dermatology Conference
      • Sep 20, 2019: Hovione announces successful end-of-phase 2 meeting with the FDA and outlines phase 3 program for minocycline topical gel
      • Aug 06, 2019: Foamix seeks FDA approval for FMX103 to treat rosacea
      • Jul 08, 2019: Sol-Gel announces positive top-line results from epsolay phase 3 program in papulopustular Rosacea
      • Jun 26, 2019: BioPharmX reports positive results from BPX-041 trial for rosacea
      • May 22, 2019: BioPharmX announces last patient visit in Phase 2b trial of BPX-04 for papulopustular rosacea
      • Mar 04, 2019: BioPharmX completes enrollment in phase 2b trial of BPX-04 for patients with papulopustular rosacea
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q